Immunocore Holdings PLC 8-K filings

Immunocore announced robust second-quarter financial results, driven by significant year-over-year revenue growth for its lead drug KIMMTRAK, alongside encouraging updates on its clinical pipeline.

Immunocore Holdings plc announced that all ten resolutions presented at its 2026 Annual General Meeting of Shareholders on May 27, 2026, were duly passed by shareholders.

Immunocore Holdings plc announced first quarter 2026 financial results, highlighting a 14% year-over-year increase in KIMMTRAK net sales to $106.7 million and positive five-year survival data.

Immunocore Holdings plc announced robust fourth quarter and full year 2025 financial results, driven by strong KIMMTRAK sales and significant progress across its oncology, infectious disease, and autoimmune pipelines.

Immunocore Holdings plc announced the resignation of its Head of Research & Development, David Berman, effective February 27, 2026, with the company opting to streamline its existing R&D structure.

Immunocore Holdings plc announced its 2026 strategic priorities, highlighted by clinical trial advancements across oncology, infectious, and autoimmune diseases, alongside a preliminary year-end 2025 cash position of $864 million.

Immunocore Holdings plc announced the immediate resignation of a board member and the future departure of its Chief Human Resources Officer.

Immunocore Holdings plc announced robust third-quarter 2025 financial results, with KIMMTRAK net revenues growing 29% year-over-year, alongside significant progress in its Phase 3 clinical trials for melanoma and other therapeutic areas.

Immunocore Holdings plc announced robust second quarter 2025 financial results with significant revenue growth for KIMMTRAK and advancement across its oncology, infectious disease, and autoimmune pipelines.

Immunocore Holdings plc held its 2025 Annual General Meeting on May 15, 2025, where shareholders voted on and passed thirteen resolutions.

Immunocore announces a 33% year-over-year increase in KIMMTRAK net revenues, reaching $93.9 million in Q1 2025, and provides updates on its clinical pipeline.

Immunocore Holdings plc amended its indenture governing its 2.50% Convertible Senior Notes due 2030 and filed a prospectus supplement for the resale of up to $150 million of these notes and related American Depositary Shares (ADSs).

Immunocore's IMC-M113V shows promising initial data in HIV patients, demonstrating good tolerability and signals of dose-dependent viral control after antiretroviral treatment interruption.

Immunocore announces positive financial results for Q4 and full year 2024, driven by KIMMTRAK sales growth and progress in clinical pipeline development.

Immunocore outlines its 2025 strategic priorities, including expanding the reach of KIMMTRAK and advancing its clinical pipeline, while also reporting a preliminary cash position of approximately $820 million as of December 31, 2024.

Immunocore has appointed Travis Coy as its new Executive Vice President, Chief Financial Officer, and Head of Corporate Development, effective January 1, 2025.

Immunocore Holdings subsidiary, Immunocore Limited, fully prepaid its $52 million loan under the Pharmakon Loan Agreement, effectively terminating the agreement.

Immunocore announced a strong third quarter with significant revenue growth for KIMMTRAK and progress in its clinical pipeline.

Immunocore announced positive Phase 1 clinical trial results for brenetafusp in heavily pre-treated ovarian cancer patients, both as a monotherapy and in combination with chemotherapy, and highlighted the importance of T cell fitness as a biomarker for clinical activity.

Immunocore's Chief Financial Officer, Brian Di Donato, will resign at the end of 2024 to become CEO of a private biotech company, prompting a search for his replacement.

Immunocore announced a 32% increase in KIMMTRAK sales for Q2 2024, alongside updates on multiple clinical trials and pipeline advancements.

Immunocore's brenetafusp shows encouraging disease control and progression-free survival in pre-treated cutaneous melanoma patients, particularly those with PRAME-positive tumors.

Immunocore's TEBE-AM Phase 2/3 clinical trial for advanced cutaneous melanoma has been converted to a single Phase 3 registrational trial after discussions with the FDA, aiming to accelerate the approval process for KIMMTRAK.

Immunocore Holdings plc has appointed Ranjeev Krishana to its Board of Directors and entered into a new registration rights agreement with Baker Brothers Funds, granting them certain resale registration rights.

Immunocore Holdings plc successfully held its 2024 Annual General Meeting, with shareholders approving all eleven resolutions presented.

Immunocore announced a 36% increase in KIMMTRAK revenue year-over-year for Q1 2024, alongside advancements in its clinical pipeline.

Immunocore Holdings has filed a prospectus supplement for the resale of up to 1,220,063 American Depositary Shares by a selling shareholder.

Immunocore announced its fourth quarter and full year 2023 financial results, highlighting significant revenue growth for KIMMTRAK and progress across its clinical programs.

Immunocore Holdings plc has successfully priced an upsized private offering of $402.5 million in convertible senior notes due 2030, with the proceeds intended for clinical pipeline acceleration and commercial expansion.

Immunocore reports preliminary 2023 revenue of $235 million and announces a $300 million convertible notes offering to accelerate clinical pipeline and commercial expansion.